Latest News & Updates of Loncom Pharma

Loncom Pharma analyzes FDA ANDA bioequivalence updates and supports global generic drug development strategies.

NMPA's July 2026 announcement specifies four scenarios for chemical API priority review, effective 1 August.

ICH E6(R3) Annex 2 provides GCP guidance for decentralised, pragmatic, and RWD‑enriched trials. It emphasises proportionality, QbD, patient engagement, and early regulator dialogue, reshaping clinical trial quality management for the digital era.